Psychology Today

Reviving the Original Meaning of Borderline

Discover why decades of research now challenge the BPD diagnosis — and how new models may offer clearer, less stigmatizing ways forward.
WDTN

Oryzon Defines Phase III Trial Endpoints for Agitation and Aggression in BPD with Input From New Clinical Advisory Board

Leading US psychiatric experts join Oryzon’s Clinical Advisory Board (CAB) to advance Phase III development of vafidemstat in Borderline Personality Disorder (BPD) CAB and Oryzon establish primary and ...
Morningstar

ORYZON receives minutes from End-of-Phase II meeting with the FDA on the PORTICO-2 Phase III vafidemstat trial in Borderline Personality Disorder

Agitation-Aggression in Borderline Personality Disorder (BPD) acknowledged as a possible therapeutic indication Oryzon may use STAXI-2 Trait anger as a primary efficacy endpoint for PORTICO-2 ...